Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.51 (¥3,470)+0.93%▲ (in JPY terms)
SoftBank|$33.62 (¥5,424)-9.01%▼ (in JPY terms)
MUFG|$21.53 (¥3,473)-4.30%▼ (in JPY terms)
Keyence|$439.33 (¥70,880)-4.28%▼ (in JPY terms)
Nintendo|$45.21 (¥7,294)+3.02%▲ (in JPY terms)
NTT|$0.94 (¥151)+0.13%▲ (in JPY terms)
Takeda|$33.97 (¥5,480)+2.53%▲ (in JPY terms)
Tokyo Electron|$403.50 (¥65,100)-8.17%▼ (in JPY terms)
Recruit|$79.46 (¥12,820)+1.63%▲ (in JPY terms)
ITOCHU|$11.79 (¥1,903)-0.89%▼ (in JPY terms)
Honda|$9.52 (¥1,536)-1.48%▼ (in JPY terms)
Shin-Etsu|$44.36 (¥7,157)-2.77%▼ (in JPY terms)
Tokio Marine|$46.65 (¥7,526)-0.97%▼ (in JPY terms)
Fast Retailing|$488.67 (¥78,840)+0.00%▲ (in JPY terms)
Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.51 (¥3,470)+0.93%▲ (in JPY terms)
SoftBank|$33.62 (¥5,424)-9.01%▼ (in JPY terms)
MUFG|$21.53 (¥3,473)-4.30%▼ (in JPY terms)
Keyence|$439.33 (¥70,880)-4.28%▼ (in JPY terms)
Nintendo|$45.21 (¥7,294)+3.02%▲ (in JPY terms)
NTT|$0.94 (¥151)+0.13%▲ (in JPY terms)
Takeda|$33.97 (¥5,480)+2.53%▲ (in JPY terms)
Tokyo Electron|$403.50 (¥65,100)-8.17%▼ (in JPY terms)
Recruit|$79.46 (¥12,820)+1.63%▲ (in JPY terms)
ITOCHU|$11.79 (¥1,903)-0.89%▼ (in JPY terms)
Honda|$9.52 (¥1,536)-1.48%▼ (in JPY terms)
Shin-Etsu|$44.36 (¥7,157)-2.77%▼ (in JPY terms)
Tokio Marine|$46.65 (¥7,526)-0.97%▼ (in JPY terms)
Fast Retailing|$488.67 (¥78,840)+0.00%▲ (in JPY terms)

Astellas Pharma Inc.

2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab, regardless of whether cisplatin is indicated, as a neoadjuvant therapy for muscle-invasive bladder cancer, and has granted it priority review.”

by

2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug c … 続きを読む

2026-03-23 Astellas Pharma Inc. “The EMA has received an application for approval of an additional indication for the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for muscle-invasive bladder cancer already treated with cisplatin.”

by

2026-03-23 Astellas Pharma Inc. “The EMA has received an application for approval of an additional indic … 続きを読む

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in cisplatin-eligible muscle-invasive bladder cancer were presented at the 2026 American Society of Clinical Oncology (ASCO GU) Annual Meeting.”

by

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate … 続きを読む

Contact